Rajesh K. Rajpal

About Rajesh K. Rajpal

Rajesh K. Rajpal is an internationally recognized ophthalmologist, innovator, and industry leader shaping the future of health care and surgical innovation with a proven track record of guiding companies through clinical, regulatory, and commercial milestones.

Alongside his corporate leadership, Rajpal founded and built See Clearly Vision Group – a multi-location ophthalmology and optometry practice – into one of the Washington, DC area’s premier specialty providers. He led its acquisition and integration into Vision Innovation Partners, a private equity–backed ophthalmology platform, where he continues to provide patient care and perform surgery

Rajpal currently serves as the industry representative on the FDA’s Ophthalmic Devices Panel, is on the Board of Directors for NAEVR/AEVR, and contributes to clinical research and education globally. A frequent speaker at international conferences, he has authored numerous peer-reviewed publications and served as principal investigator on multiple clinical trials. He is the Cornea Consultant to Walter Reed National Military Medical Center and a Clinical Professor of Ophthalmology at George Washington University Medical Center.

At Horizon, the first ever robotic cataract surgery in patients was performed in October 2025 and plans for clinical trials are underway. From J&J, the Tecnis Odyssey and Pursee IOLs, as well as the Elita femtosecond laser have been commercially launched with outstanding acceptance globally after the earlier successful launch of the Tecnis Eyehance IOL. In addition, Raj is assisting Glaukos with the commercial launch of the first and only FDA approved epithelium-on corneal crosslinking procedure (Epi-Oxa) based on studies that were initiated while he was Chief Medical Officer at Avedro.